Izar, Benjamin
Tirosh, Itay http://orcid.org/0000-0001-5477-2987
Stover, Elizabeth H. http://orcid.org/0000-0002-6578-3216
Wakiro, Isaac http://orcid.org/0000-0002-5248-4823
Cuoco, Michael S. http://orcid.org/0000-0003-2163-5120
Alter, Idan
Rodman, Christopher
Leeson, Rachel
Su, Mei-Ju
Shah, Parin
Iwanicki, Marcin http://orcid.org/0000-0001-8375-8447
Walker, Sarah R.
Kanodia, Abhay
Melms, Johannes C.
Mei, Shaolin
Lin, Jia-Ren http://orcid.org/0000-0003-4702-7705
Porter, Caroline B. M.
Slyper, Michal
Waldman, Julia
Jerby-Arnon, Livnat
Ashenberg, Orr
Brinker, Titus J.
Mills, Caitlin http://orcid.org/0000-0002-2608-4084
Rogava, Meri
Vigneau, Sébastien
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
Garraway, Levi A.
Konstantinopoulos, Panagiotis A. http://orcid.org/0000-0002-1032-1479
Liu, Joyce F.
Matulonis, Ursula
Johnson, Bruce E.
Rozenblatt-Rosen, Orit http://orcid.org/0000-0001-6313-3570
Rotem, Asaf
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R33-CA202820, P30CA14051, K08CA222663)
Howard Hughes Medical Institute (n/A)
Article History
Received: 1 July 2019
Accepted: 7 May 2020
First Online: 22 June 2020
Competing interests
: B.I. is a consultant for Merck and Volastra Therapeutics. L.A.G. is an employee of Genentech. L.A.G. was previously an employee of Eli Lilly. L.A.G. was a paid consultant for Novartis, Foundation Medicine and Boehringer Ingelheim, held equity in Foundation Medicine and was a recipient of a grant from Novartis. P.K.S. is a member of the SAB or Board of Directors and holds equity in Applied Biomath, Glencoe Software and RareCyte. A.Rotem is a consultant to eGenesis, a member of the SAB in NucleAI and an holds equity in Celsius. A.Regev is a SAB member of Thermo Fisher Scientific, Neogene Therapeutics, Asimov and Syros Pharmaceuticals, a cofounder of and equity holder in Celsius Therapeutics, and an equity holder in Immunitas Therapeutics. B.I., I.T., E.H.S., L.A.G., O.R.-R., A.Rotem and A.Regev have filed a provisional patent for the use of JSI-124 for the treatment of ovarian cancer. The other authors have no conflicts of interest to declare.